Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia.
autonomic nervous system
long-acting injectable aripiprazole
schizophrenia, aripiprazole
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
03 03 2023
03 03 2023
Historique:
received:
02
10
2022
accepted:
20
02
2023
entrez:
3
3
2023
pubmed:
4
3
2023
medline:
8
3
2023
Statut:
epublish
Résumé
Distinct oral atypical antipsychotics have different effects on autonomic nervous system (ANS) activity. Among them, oral aripiprazole has been linked to dysfunction of the ANS in schizophrenia. Long-acting injectable aripiprazole is a major treatment option for schizophrenia, but the effect of the aripiprazole formulation on ANS activity remains unclear. In this study, we compared ANS activity between oral aripiprazole and aripiprazole once-monthly (AOM) in schizophrenia. Of the 122 patients with schizophrenia who participated in this study, 72 received oral aripiprazole and 50 received AOM as monotherapy. We used power spectral analysis of heart rate variability to assess ANS activity. Patients who received oral aripiprazole showed significantly diminished sympathetic nervous activity compared with those who received AOM. Multiple regression analysis revealed that the aripiprazole formulation significantly influenced sympathetic nervous activity. Compared with oral aripiprazole, AOM appears to have fewer adverse effects, such as sympathetic nervous dysfunction.
Sections du résumé
BACKGROUND
Distinct oral atypical antipsychotics have different effects on autonomic nervous system (ANS) activity. Among them, oral aripiprazole has been linked to dysfunction of the ANS in schizophrenia. Long-acting injectable aripiprazole is a major treatment option for schizophrenia, but the effect of the aripiprazole formulation on ANS activity remains unclear. In this study, we compared ANS activity between oral aripiprazole and aripiprazole once-monthly (AOM) in schizophrenia.
METHODS
Of the 122 patients with schizophrenia who participated in this study, 72 received oral aripiprazole and 50 received AOM as monotherapy. We used power spectral analysis of heart rate variability to assess ANS activity.
RESULTS
Patients who received oral aripiprazole showed significantly diminished sympathetic nervous activity compared with those who received AOM. Multiple regression analysis revealed that the aripiprazole formulation significantly influenced sympathetic nervous activity.
CONCLUSION
Compared with oral aripiprazole, AOM appears to have fewer adverse effects, such as sympathetic nervous dysfunction.
Identifiants
pubmed: 36869320
doi: 10.1186/s12888-023-04617-y
pii: 10.1186/s12888-023-04617-y
pmc: PMC9983165
doi:
Substances chimiques
Aripiprazole
82VFR53I78
Antipsychotic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
135Informations de copyright
© 2023. The Author(s).
Références
Eur J Clin Pharmacol. 2018 May;74(5):593-599
pubmed: 29392351
Psychopharmacology (Berl). 2022 Jan;239(1):243-251
pubmed: 34989824
Neuropsychobiology. 2001;44(3):129-33
pubmed: 11586052
Psychopharmacology (Berl). 2022 Nov;239(11):3377-3391
pubmed: 36195732
Schizophr Res. 2021 Nov;237:9-19
pubmed: 34478937
Neuropsychiatr Dis Treat. 2018 Sep 17;14:2361-2366
pubmed: 30271152
JAMA Psychiatry. 2015 Dec;72(12):1172-81
pubmed: 26509694
Schizophr Res. 2011 Apr;127(1-3):83-92
pubmed: 21257294
Schizophr Bull. 2018 Oct 17;44(6):1381-1387
pubmed: 29272458
Acta Neuropsychiatr. 2013 Jun;25(3):155-64
pubmed: 25287469
Schizophr Bull. 2014 Jan;40(1):192-213
pubmed: 23256986
Sci Rep. 2014 Dec 09;4:7394
pubmed: 25487560
Psychiatry Clin Neurosci. 2015 Aug;69(8):440-7
pubmed: 25601291
Psychiatry Clin Neurosci. 2009 Aug;63(4):538-45
pubmed: 19496998
Int J Cardiol. 2010 May 28;141(2):122-31
pubmed: 19910061
J Clin Psychopharmacol. 2013 Apr;33(2):170-7
pubmed: 23422372
J Clin Psychopharmacol. 2017 Jun;37(3):289-295
pubmed: 28350572
Innov Clin Neurosci. 2013 Mar;10(3):23-30
pubmed: 23630647
Eur Psychiatry. 2013 Feb;28(2):81-6
pubmed: 21920708
J Clin Psychiatry. 2002 Sep;63(9):763-71
pubmed: 12363115
Prim Care Companion CNS Disord. 2021 Sep 30;23(5):
pubmed: 34592798
J Clin Psychopharmacol. 2013 Jun;33(3):398-404
pubmed: 23609386
Schizophr Res. 2018 Jul;197:274-280
pubmed: 29274734
BMC Psychiatry. 2018 Jul 17;18(1):231
pubmed: 30016952
Innov Clin Neurosci. 2012 Jul;9(7-8):17-23
pubmed: 22984648
JAMA Psychiatry. 2015 Apr;72(4):334-41
pubmed: 25671328
Riv Psichiatr. 2014 May-Jun;49(3):115-23
pubmed: 25000887
Int Clin Psychopharmacol. 2005 Mar;20(2):71-8
pubmed: 15729081
Clin Pharmacol Drug Dev. 2022 Feb;11(2):150-164
pubmed: 34979059
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
J Clin Psychiatry. 2013 Oct;74(10):957-65
pubmed: 24229745
Ther Adv Psychopharmacol. 2022 Jul 30;12:20451253221113238
pubmed: 35923249
BMC Psychiatry. 2012 Nov 14;12:199
pubmed: 23151241
J Electromyogr Kinesiol. 2005 Jun;15(3):240-55
pubmed: 15763671
Schizophr Res. 2018 Mar;193:134-138
pubmed: 28709776
Nihon Yakurigaku Zasshi. 2006 Nov;128(5):331-45
pubmed: 17102579
Br J Psychiatry. 2016 Jan;208(1):9-16
pubmed: 26729841
Acta Psychiatr Scand. 2016 Jan;133(1):44-52
pubmed: 26371411
JAMA Psychiatry. 2017 Jul 1;74(7):686-693
pubmed: 28593216
Schizophr Res. 2021 May;231:42-46
pubmed: 33752105
BMC Psychiatry. 2020 Feb 18;20(1):72
pubmed: 32070304
J Pharmacol Exp Ther. 2002 Jul;302(1):381-9
pubmed: 12065741
Compr Psychiatry. 2018 Oct;86:119-122
pubmed: 30118994
Adv Ther. 2020 Jul;37(7):3324-3336
pubmed: 32500455